Aurinia Pharmaceuticals Inc.

NASDAQ:AUPH

Biotechnology

Healthcare
$15.13 +0.81%

+$0.13 today

Market cap
$2.03B
Beta
1.43
P/E (TTM)
7.2
EPS (TTM)
$2.25
52W Low $7.29High $16.88

Volume 0.76M

Average 1.21M

AUPH Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Aurinia Pharmaceuticals Inc.NASDAQ: AUPH

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin widens to 92.1%

Gross margin was 92.1% in Q2 FY2026, up 2.3 pp from a year earlier. On a trailing-twelve-month basis it was 90.4%, up 0.8 pp year over year. Over 3 fiscal years it narrowed by 7.3 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
92.1%+0.5 pp QoQ
Last fiscal yearDec 2025
88.5%+0.5 pp YoY
LTMJun 2026
90.4%+0.8 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+2.3 pp——
1 year+0.5 pp——
3 years-7.3 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
88.5%
Year-over-year change
+0.5pp

Gross Margin vs competitors

How AUPH compares with its peers on the latest reported figures

  • AUPH's LTM Jun 2026 gross margin of 90.4% is the 2nd highest of the 5 companies compared; the peer median is 82.3%.
  • Its year-over-year change of +0.8 pp is the 2nd highest of 3, against a peer median of +24.0 pp.
  • Over three fiscal years its change of -7.3 pp compares with a peer median of +13.5 pp.
AUPH Competitors Peer median
Gross Margin for AUPH and competitors
Company Period LTM level YoY 3-year change
EVMNEvommune, Inc.LTM Mar 202692.8% ——
AUPHAurinia Pharmaceuticals Inc.LTM Jun 202690.4% +0.8 pp-7.3 pp
ALMSAlumis Inc. Common StockLTM Jun 202688.2% -7.7 pp—
ACRSAclaris Therapeutics, Inc.LTM Mar 202676.3% +55.8 pp+13.5 pp
ATTOAttovia Therapeutics, Inc.FY202540.4% ——
BHVNBiohaven Ltd.FY2025— ——
VERAVera Therapeutics, Inc.FY2025— ——
TRAXFirst Tracks Biotherapeutics IncFY2025— ——
MLTXMoonLake ImmunotherapeuticsFY2025— ——
ELDNEledon Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding AUPH) 82.3%+24.0 pp+13.5 pp

Competitors are the stored peer set for AUPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue45.61M134.03M175.51M235.13M283.06M
Cost of Revenue1.09M5.66M14.15M28.25M32.67M
Gross Profit44.51M128.37M161.37M206.89M250.39M
Gross Margin97.6%95.8%91.9%88.0%88.5%
Research & Development51.14M44.99M49.64M20.79M32.51M
Selling, General & Admin171.44M196.37M195.04M172.03M101.79M
Operating Expenses225.25M239.84M253.06M211.57M145.48M
Depreciation & Amortization2.76M2.71M11.65M19.45M9.27M
EBITDA(177.45M)(103.65M)(63.05M)31.73M127.76M
EBITDA Margin-389.1%-77.3%-35.9%13.5%45.1%
Operating Income(180.74M)(111.47M)(91.69M)(4.69M)104.91M
Operating Margin-396.3%-83.2%-52.2%-2.0%37.1%
Interest Income529K5.12M17M16.97M13.57M
Interest Expense002.78M4.84M4.33M
Other Income / Expenses529K5.12M14.22M12.14M9.24M
Income Before Tax(180.21M)(106.35M)(77.47M)7.45M114.16M
Pre-Tax Margin-395.1%-79.3%-44.1%3.2%40.3%
Income Tax Expense760K1.83M551K1.7M(173.05M)
Net Income(180.97M)(108.18M)(78.02M)5.75M287.2M
Net Margin-396.8%-80.7%-44.5%2.4%101.5%
EPS (Basic)(1.40)(0.76)(0.54)0.042.14
EPS (Diluted)(1.40)(0.76)(0.54)0.042.07
Weighted Avg Shares129.37M141.92M143.24M143.06M134.37M
Weighted Avg Shares (Diluted)129.37M141.92M143.24M146.19M138.7M

Aurinia Pharmaceuticals Inc.

NASDAQ:AUPH

Intrinsic Alpha fair value

Locked

Current Price

$15.13

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.